Loading...
OTCM
NORD
Market cap17mUSD
Jul 09, Last price  
3.39USD
1D
15.57%
1Q
53.48%
Jan 2017
6,684.00%
Name

Nordicus Partners Corp

Chart & Performance

D1W1MN
OTCM:NORD chart
P/E
P/S
3,932.17
EPS
Div Yield, %
Shrs. gr., 5y
81.92%
Rev. gr., 5y
-72.78%
Revenues
5k
+100.00%
22,381,00021,151,0003,207,0003,265,0002,117,0001,666,0001,866,0002,195,0002,626,0002,574,0003,181,0002,284,0002,918,0003,346,0002,698,0000002,5005,000
Net income
-3m
L+872.94%
-10,138,000-5,924,000-12,180,000-5,034,000-3,376,000-6,370,000-3,624,000-1,351,000-835,000-704,000-338,000-877,000-585,000-83,000-408,000-326,000-265,000-8,464,925,000-298,202-2,901,321
CFO
-1m
L+396.13%
-1,683,000-2,259,000-3,652,000-2,723,000-1,613,000-2,592,000-1,752,000-484,000119,000-187,00062,000-203,000108,00081,0005,333,000-323,000-282,000-368,347,000-258,928-1,284,615

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Currently, EKIMAS Corporation does not engage in significant business operations. In its earlier years, the company focused on creating specialized polymer materials used in the development of medical devices, designed to address various anatomical regions and health issues. The firm's current objective is to identify, acquire, or combine with an existing operating entity through an equity-for-equity transaction. Established in 1993, this Las Vegas, Nevada-based entity was formerly known as AdvanSource Biomaterials Corporation, changing its name to EKIMAS Corporation in March 2020.
IPO date
Jun 12, 1996
Employees
11
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT